Evidence map›Paper›PMID 28397878›Full record

ArticleScientific reports2017

A novel Time-resolved Fluoroimmunoassay for the quantitative detection of Antibodies against the Phospholipase A2 Receptor.

Biao Huang, Liang Wang, Yi Zhang, Jue Zhang, Qiuhua Zhang, Hualong Xiao, Bin Zhou, Zhuxing Sun, Ya-Nan Cao, Yu Chen and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Nanomaterials Used in Fluorescence Polarization Based Biosensors.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Biao HuangJiangsu Institute of Nuclear Medicine, Wuxi, 214063, China.
Liang WangWuxi People's Hospital affiliated to Nanjing Medical University, Wuxi, 214023, China.
Yi ZhangJiangsu Institute of Nuclear Medicine, Wuxi, 214063, China.
Jue ZhangJiangsu Institute of Nuclear Medicine, Wuxi, 214063, China.
Qiuhua ZhangWuxi People's Hospital affiliated to Nanjing Medical University, Wuxi, 214023, China.
Hualong XiaoWuxi People's Hospital affiliated to Nanjing Medical University, Wuxi, 214023, China.
Bin ZhouJiangsu Institute of Nuclear Medicine, Wuxi, 214063, China.
Zhuxing SunWuxi People's Hospital affiliated to Nanjing Medical University, Wuxi, 214023, China.
Ya-Nan CaoTongren Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, 200336, China.
Yu ChenThe First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Zhigang HuWuxi People's Hospital affiliated to Nanjing Medical University, Wuxi, 214023, China.
Huiming ShengTongren Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, 200336, China.
Wuxi People's Hospital · CNShanghai Jiao Tong University · CNNanjing Medical University · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A highly sensitive time-resolved fluoroimmunoassay (TRFIA) was developed to quantify serum antibodies against the phospholipase A2 receptor (anti-PLA2R-IgG) for differential diagnosis of membranous nephropathy. Recombinant PLA2R (rPLA2R) was coated onto 96-well plates as a capture. A goat-anti-human IgG tracer was prepared with europium-chelate for detection. After bound/free separation by washing, the fluorescence counts of bound tracer were measured for quantifying serum anti-PLA2R-IgG concentration. A purified anti-PLA2R-IgG calibrator was first prepared for ensuring that consistent quantitative results could be obtained. The assay detection limit was 0.03 mg/L with linear measurement range of 0.03-340 mg/L. The intra- and inter-assay coefficients of variation (CVs) were 3.8% and 6.2%, respectively. The average serum anti-PLA2R-IgG concentration in 45 healthy volunteers, 31 IgA nephropathy, 9 lupus nephropathy, and 52 idiopathic membranous nephropathy patients was 0.53 ± 0.18 mg/L, 0.70 ± 0.41 mg/L, 1.08 ± 0.65 mg/L, and 9.00 ± 11.82 mg/L, respectively. The cut-off point for an abnormal anti-PLA2R-IgG concentration was defined as >0.89 mg/L. The positive rates in serum from patients with IgA nephropathy, lupus nephropathy, and idiopathic membranous nephropathy were 29.0%, 44.4%, and 88.5%, respectively. The availability of this quantitation method will facilitate the use of serum anti-PLA2R-IgG for diagnosing idiopathic membranous nephropathy.

Indexed as

AntibodiesCalibrationEnzyme-Linked Immunosorbent AssayFluoroimmunoassayHumansImmunoglobulin GKidney DiseasesReceptors, Phospholipase A2Time FactorsAntibodiesImmunoglobulin GReceptors, Phospholipase A2

Identifiers

PMID28397878
PMCPMC5387400
OpenAlexW2605703130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.